BioCentury | Jun 20, 2016
Product Development

Predictive potential

CytoploRare from Geno Biotech Co. Ltd. is the first circulating tumor cell test approved in China to diagnose lung cancer. With greater sensitivity and specificity in the indication than other CTC tests that are used...
BC Innovations | Jun 2, 2016
Product R&D

Local reagent makes good

Genisphere LLC is converting its 19 year-old diagnostic reagents into new-age delivery vehicles. The company is repurposing its 3DNA assay technology into nanoparticles that it believes can bring high-valency cargo to target tissues without getting...
BC Innovations | Jan 9, 2014
Cover Story

Light it up

Poor tumor definition is a central challenge in cancer surgery, which aims to remove all malignant cells while preserving normal tissue. Now, a team from The University of Texas Southwestern Medical Center has designed fluorescent...
BioCentury | Apr 23, 2012

Merck's platinum play

Merck & Co. Inc. has sifted through seemingly conflicting data and concluded the PFS benefit in a Phase II trial in platinum-resistant ovarian cancer was robust enough to justify paying $120 million up front for...
BC Innovations | Jun 2, 2011
Distillery Techniques

Technology: Drug delivery

Approach Summary Licensing status Publication and contact information Drug delivery Folic acid-coated nanoparticles for gene therapy Folic acid-coated nanoparticles could help increase the safety and efficacy of gene therapy. Polyethylenimine-plasmid DNA complexes were coated with...
BioCentury | May 9, 2011

Looking for better conditions

Endocyte Inc. 's plans for EC145 in ovarian cancer illustrate the divide between FDA and EMA on early approval of drugs based on progression-free survival. The company plans to seek conditional approval in the EU...
BioCentury | Jun 21, 2010
Product Development

Targeting ovarian

Successes with targeted therapies in solid tumors such as colon, breast and lung cancers have led several companies to explore targeted treatment approaches in ovarian cancer, including antiangiogenics and ligand-targeted chemotherapeutics. Presentations at this year's...
BC Week In Review | Nov 2, 2009
Clinical News

EC145: Preliminary Phase IIa data

Preliminary data from a Phase IIa trial in 49 women with advanced, chemotherapy-resistant ovarian cancer showed that EC145 resulted in disease control, defined as stable disease, partial or complete response as measured by RECIST criteria...
BC Innovations | Jul 17, 2008
Distillery Techniques

This Week in Techniques

This week in techniques Approach Summary Licensing status Publication and contact information Tumor-targeted photodynamic therapy An in vitro study suggests that folic acid conjugates could be useful for targeting photodynamic therapy to tumor cells. A...
BC Innovations | Feb 21, 2008
Tools & Techniques

Serial killing nanocarriers

Among the challenges facing researchers in designing tumor-targeted drug delivery systems are choosing a ligand that selectively targets the tumor and consistently delivering therapeutic payload to all parts of the tumor. A group at the...
Items per page:
1 - 10 of 11